This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
2viw
From Proteopedia
| |||||||
| , resolution 2.05Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | and | ||||||
| Ligands: | , | ||||||
| Activity: | U-plasminogen activator, with EC number 3.4.21.73 | ||||||
| Related: | 1C5W, 1C5X, 1C5Y, 1C5Z, 1EJN, 1FV9, 1GI7, 1GI9, 1GJ7, 1GJ8, 1GJ9, 1GJC, 1KDU, 1O5C, 1OWD, 1OWH, 1OWJ, 1SC8, 1F5L, 1F92, 1GI8, 1GJA, 1GJB, 1GJD, 1LMW, 1O3P, 1O5A, 1O5B, 1OWE, 1OWI, 1OWK, 1SQA, 1SQO, 1SQT, 1U6Q, 1VJ9, 1W0Z, 1W10, 1W12, 1W14, 1VJA, 1W11, 1W13, 2JDE, 2VIN, 2VIO, 2VIP, 2VIQ, 2VIV
| ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
Overview
Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
About this Structure
2VIW is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator., Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M, Wallis NG, J Med Chem. 2008 Jan 24;51(2):183-6. Epub 2007 Dec 29. PMID:18163548
Page seeded by OCA on Mon Mar 31 05:12:57 2008
Categories: Homo sapiens | Single protein | U-plasminogen activator | Callaghan, O. | Chessari, G. | Congreve, M. | Cowan, S R. | Frederickson, M. | Matthews, J E. | Mcmenamin, R. | Smith, D. | Vinkovic, M. | Wallis, N G. | Blood coagulation | Egf-like domain | Fibrinolysis | Glycoprotein | Hydrolase | Inhibitor | Kringle | Pharmaceutical | Phosphorylation | Plasminogen activation | Polymorphism | Protease | Secreted | Serine protease | Urokinase-type plasminogen activator | Zymogen
